Duramed (DRMD) Synthetic Estrogen Product Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Duramed (DRMD) Synthetic Estrogen Product

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tommysdad who wrote (499)	12/30/1997 11:18:00 PM
From: Steve Rubakh	Read Replies (1) of 1837

The Wall Street Journal Interactive Edition -- December 30, 1997 Duramed's Shares Surge As FDA Approves Drug Dow Jones Newswires CINCINNATI -- Shares of Duramed Pharmaceuticals Inc. surged Tuesday after the company received U.S. Food and Drug Administration approval to market Estradiol tablets, a women's hormone-replacement therapy. In late day trading on the Nasdaq Stock Market, Duramed's stock was up $1.6563, or 54%, to $4.6875, on volume of 1.8 million shares, compared with average daily volume of about 200,000. The Cincinnati maker of generic prescription drugs said the FDA designated Estradiol tablets as completely interchangeable with Estrace tablets. Estrace is an estrogen-replacement drug made by Bristol-Myers Squibb Co. The FDA cleared the company to sell Estradiol in 0.5 milligram, 1 mg, 1.5 mg and 2 mg strengths. Duramed noted that the 1.5 mg Estradiol tablet dosage is a strength not currently available from any other source. Shipments of Estradiol, which is used to treat symptoms of menopause and prevent osteoporosis, should begin in January. Barr Laboratories Inc. and Watson Pharmaceuticals Inc. also sell generic versions of Estrace

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next